We recently published 10 Stocks Taking the Worst Hit. Vertex Inc. (NASDAQ:VERX) is one of the worst-performing stocks on ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

NEW YORK, NY-Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, has been named one of the 100 Most Powerful ...

Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...

Vertex CFTR modulators, led by Trikafta, brought in more than $9.8 billion in revenue last year, an 11% increase. Trikafta's dominance could continue -- or it may be unseated by an up-and-coming ...

At 23.8 times forward earnings, Vertex stock trades in line with the broader S&P 500 index, which is at 23.6 times earnings -- a surprising valuation for a company with a dominant market share and ...

Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S ...